NetNoggin® releases exploratory analysis "Psychographics for TRIKAFTA™, the new treatment by Vertex for patients with cystic fibrosis."
FREDERICK, Md., Dec. 12, 2019 /PRNewswire/ -- A new exploratory study, conducted by NetNoggin®, highlights the attitudes and beliefs of patients and caregivers regarding the approval of TRIKAFTA™ in the cystic fibrosis market.
Visit https://netnoggin.net/exploratory-analysis to request the full exploratory analysis.
Director of NetNoggin®, Megan Newcomer, explains how this market disruption affects the patient journey, "The FDA's approval of TRIKAFTA™ has been a huge advancement in the cystic fibrosis market. This advancement will shift our understanding of the patient journey. A patient journey typically remains consistent unless there is a major market disruption, such as the approval of a new treatment (like TRIKAFTA™). Pharmaceutical companies within the cystic fibrosis market need to prepare for how this will affect their strategy and launch by understanding how the market will shift and evolve."
NetNoggin® is also updating their syndicated report, NetNog: #genesis® Cystic Fibrosis, to reflect these changes in the market due to TRIKAFTA™. NetNoggin® will continue to follow the patient journey disruption from January 1, 2020 to June 30, 2020. NetNoggin® is offering monthly updates of the report from January 2020 to June 2020 with the purchase of NetNog: #genesis® Cystic Fibrosis. A sneak peek of the NetNog: #genesis® Cystic Fibrosis research report is in the appendix of the Exploratory Analysis: Psychographics for TRIKAFTA™.
About NetNog: #genesis® Cystic Fibrosis
NetNoggin® Media Relations
View original content to download multimedia:http://www.prnewswire.com/news-releases/netnoggin-releases-exploratory-analysis-psychographics-for-trikafta-the-new-treatment-by-vertex-for-patients-with-cystic-fibrosis-300974101.html